[go: up one dir, main page]

NO20093540L - Formuleringer for forlenget frigivning omfattende quetiapin og fremgangsmater for fremstilling derav - Google Patents

Formuleringer for forlenget frigivning omfattende quetiapin og fremgangsmater for fremstilling derav

Info

Publication number
NO20093540L
NO20093540L NO20093540A NO20093540A NO20093540L NO 20093540 L NO20093540 L NO 20093540L NO 20093540 A NO20093540 A NO 20093540A NO 20093540 A NO20093540 A NO 20093540A NO 20093540 L NO20093540 L NO 20093540L
Authority
NO
Norway
Prior art keywords
quetiapine
formulations
preparing
methods
extended release
Prior art date
Application number
NO20093540A
Other languages
English (en)
Inventor
Daniel Brown
Donna Caster
Brian Clark
Sandra Hopkins
Jennifer Llewe-Lyn
Lisa Martin
Elizabeth Meehan
Robert Timko
Husheng Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20093540L publication Critical patent/NO20093540L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Preparater for forlenget frigivning og fremgangsmåter for fremstilling derav. Formuleringer for forlenget frigivning av quetiapin og farmasøytisk akseptable salter, og metoder for fremstilling av formuleringene, kan inkludere bruken av polymerer valgt med henblikk på deres fysiske og kjemiske karakteristika. Formuleringene kan inkludere polymerer valgt for å kunne bruke faste doseringsformer av formuleringene for tilpasning til på forhånd valgt quetiapin frigivningskarakteristika. Formuleringene kan inkludere ikke-polymermaterialer som kan bevirke quetiapinfrigivning.
NO20093540A 2007-05-16 2009-12-16 Formuleringer for forlenget frigivning omfattende quetiapin og fremgangsmater for fremstilling derav NO20093540L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93064307P 2007-05-16 2007-05-16
PCT/SE2007/001014 WO2008060228A1 (en) 2006-11-17 2007-11-16 Extended release formulations comprising quetipine and methods for their manufacture

Publications (1)

Publication Number Publication Date
NO20093540L true NO20093540L (no) 2009-12-16

Family

ID=40028121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093540A NO20093540L (no) 2007-05-16 2009-12-16 Formuleringer for forlenget frigivning omfattende quetiapin og fremgangsmater for fremstilling derav

Country Status (12)

Country Link
US (2) US20080287418A1 (no)
EP (1) EP2160183A4 (no)
JP (1) JP2010526874A (no)
CN (1) CN101754752A (no)
BE (1) BE1018260A3 (no)
CA (1) CA2610652A1 (no)
DE (1) DE102007054788A1 (no)
FR (1) FR2908657A1 (no)
NO (1) NO20093540L (no)
PT (1) PT103884A (no)
SE (1) SE0702522L (no)
WO (1) WO2008060228A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036654B (zh) * 2008-07-24 2014-05-14 湖南洞庭药业股份有限公司 稳定的非典型抗精神病制剂
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010089259A2 (en) * 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
AU2014255434B2 (en) * 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CN104586805A (zh) * 2014-07-08 2015-05-06 上海中西三维药业有限公司 富马酸喹硫平缓释片剂及其制备方法
CN113331425B (zh) * 2021-06-07 2022-06-14 中国农业大学 一种软骨多糖缓释剂及其制备方法与应用
AU2023379983A1 (en) 2022-11-15 2025-05-22 Basf Agrochemical Products B.V. Aqueous suspension concentrate formulations of agrochemical actives
WO2025035066A1 (en) * 2023-08-10 2025-02-13 Biohaven Therapeutics Ltd. Extended-release formulations of kv7.2/7.3 potassium channel activators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839319A (en) * 1973-01-26 1974-10-01 Dow Chemical Co Hydroxypropyl methylcellulose ethers and method of preparation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
WO2002045713A2 (en) * 2000-12-04 2002-06-13 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
CA2538745A1 (en) * 2003-09-23 2005-03-31 Fermion Oy Preparation of quetiapine
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
US20060188444A1 (en) * 2005-02-23 2006-08-24 Otsuka Pharmaceutical Co., Ltd. Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method

Also Published As

Publication number Publication date
CA2610652A1 (en) 2008-05-17
JP2010526874A (ja) 2010-08-05
PT103884A (pt) 2008-05-19
WO2008060228A1 (en) 2008-05-22
FR2908657A1 (fr) 2008-05-23
CN101754752A (zh) 2010-06-23
EP2160183A4 (en) 2013-02-13
US20080287418A1 (en) 2008-11-20
EP2160183A1 (en) 2010-03-10
SE0702522L (sv) 2008-05-18
DE102007054788A1 (de) 2008-07-03
BE1018260A3 (fr) 2010-08-03
US20110319383A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
NO20093540L (no) Formuleringer for forlenget frigivning omfattende quetiapin og fremgangsmater for fremstilling derav
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
NZ597059A (en) Inhibitors of influenza viruses replication
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
WO2009108730A3 (en) Forms of rifaximin and uses thereof
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
NZ604306A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2013056070A3 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
WO2009019294A3 (en) Bupropion hydrobromide and therapeutic applications
WO2013057570A3 (en) Acrylic polymer formulations
WO2008070072A3 (en) Carvedilol forms, compositions, and methods of preparation thereof
WO2011069076A3 (en) Sustained release donepezil formulations
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
IL202248A (en) Aster 4– (3-Methoxy-4-Chloro-Phenyl) Piprazine-1-Il of Acid 3– (Imidazol-2-Il) -Pyrazolo] 4,3– [b Pyridine – 1-Acetic, Methods of preparation and use in preparation of medicinal products
DK2448561T3 (da) Faste farmaceutiske fast dosis-sammensætninger omfattende irbesartan og amlodipin, deres fremstilling og deres terapeutiske anvendelse
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
CL2013000785A1 (es) Compuestos 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)(-n,n-dimetilbenzamida o –n-metilbenzamida o –benzamida); composicion farmaceutica; metodo de preparacion; producto farmaceutico; metodo de tratamiento; uso para tratar un trastorno neurologico, entre otros.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application